据悉，LAE102是自主研发针对Act RIIA的单克隆抗体，Act RIIA是在肌肉再生和脂肪代谢中发挥重要作用的受体。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。长城证券此前指，核心管线LAE002 和LAE001 商业化渐近，以增肌减脂药物LAE102为代表的自研管线具备良好创新前景。看好公司产品未来商业化发展。Kai Medical-B (02105) rose more than 11% in the morning session, as of the time of publication, up 9.79% to 17.04 Hong Kong dollars, with a turnover of 30.7419 million Hong Kong dollars.
According to the Wisdom Financial APP, Kai Medical-B (02105) rose more than 11% in the morning session, up 9.79% to 17.04 Hong Kong dollars as of publication, with a turnover of 30.7419 million Hong Kong dollars.
On the news front, on Tuesday, U.S. weight loss drug concept stocks rose across the board, with Eli Lilly rising nearly 5%, viking therapeutics rising nearly 3%, and novo-nordisk rising nearly 2%. Previously, U.S. President Biden proposed medical insurance and medical subsidies to cover weight loss drugs. It is worth noting that on November 20, Kai Medical announced that it had reached a global clinical cooperation agreement with Eli Lilly, with Eli Lilly responsible for conducting a Phase I clinical study of Kai's weight loss drug LAE102 in the United States, and bearing the related expenses.
It is reported that LAE102 is a monoclonal antibody developed independently targeting Act RIIA, a receptor that plays an important role in muscle regeneration and fat metabolism. In preclinical models, LAE102 has shown effects of increasing muscle and reducing fat. Earlier, China Great Wall Securities pointed out that the core pipeline LAE002 and LAE001 are approaching commercialization, with the self-developed pipeline represented by the muscle-building and fat-reducing drug LAE102 having good prospects for innovation. Bullish on the company's future commercial development of products.
